Integrated drug development can cut delays and improve go/no-go decisions

An integrated drug development model can help biotech teams make earlier, better decisions and reduce handoff risk across discovery, CMC, formulation and manufacturing. Case studies cited by WuXi AppTec include a targeted protein degrader program that finished material two months early and an ASO program that reached GMP manufacturing in 12 months.

Why it matters: - Integrated drug development can improve decision quality by connecting discovery, biology, chemistry, manufacturing and control, and formulation earlier in the process. - Earlier cross-functional review can expose liabilities sooner, support sharper go/no-go calls, and avoid optimizing a molecule for one stage at the expense of later development needs. - The model can also reduce handoff-related delays and execution risk, which matters for biotech teams working against tight timelines and limited resources.

What happened: - The article argues that integrated drug development offers three core advantages over managing multiple specialized vendors: better cross-functional decision-making, fewer handoff-related delays and earlier identification of downstream risks. - In a targeted protein degrader case study, a 24-step synthesis route was reduced by one-third while formulation development moved forward in parallel. - The same program eliminated a costly catalyst and produced the required material two months ahead of schedule. - In an ASO case study, discovery chemistry and process development teams worked together to address impurity and yield challenges. - That ASO program progressed through hit-to-lead optimization, process development and GMP manufacturing within 12 months.

The details: - Drug development decisions made early can reshape formulation, analytical strategy, toxicology, scale-up and manufacturing later. - A multi-vendor model can work when activities are modular, but complex programs often behave like connected systems rather than separate tasks. - Each handoff, from discovery chemistry to process development, formulation, manufacturing or preclinical to clinical supply, can introduce delays, data gaps, duplicated work or assumptions that must be revisited. - Integrated teams can evaluate candidates through multiple lenses at once, including cellular activity, in vivo translatability, physicochemical properties, developability and future manufacturing requirements. - Earlier integration of chemistry, biology and testing can help teams spot developmental bottlenecks sooner and support more reliable data for regulatory decisions. - For oligonucleotides, development can involve sequence design, modified nucleotides, conjugation, delivery, bioanalysis, metabolism, toxicology, process development, purification and manufacturing. - For extrahepatic oligonucleotide delivery, antibody format, peptide sequence, lipid properties, linker chemistry, cargo selection, receptor biology, trafficking, endosomal escape, pharmacokinetics, biodistribution and toxicology can all affect outcome.

Between the lines: - The piece frames integration as more than vendor consolidation. - The real benefit is continuity between scientific and operational decisions, so downstream teams can prepare before a project reaches them. - The examples suggest that the more technically interdependent a modality becomes, the more expensive it is to separate expertise across disconnected vendors. - That creates a structural advantage for partners that can coordinate discovery, process development and manufacturing against one shared plan.

What's next: - The article suggests biotech companies should judge partners less by how many services they offer and more by how well those services work together. - As therapies grow more complex, integrated development is likely to become more valuable for programs with tightly coupled scientific and manufacturing decisions. - Multiple specialized vendors can still work for discrete activities, but integrated models may be better suited to programs where one decision changes several downstream requirements.